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Abstract
Background: Proton pump inhibitor (PPI) medication and surgical fundoplication are used for the control of
gastro-oesophageal reflux in patients with Barrett’s oesophagus, but differ in their effectiveness for both acid and
bile reflux. This might impact on the inflammatory processes that are associated with progression of Barrett’s
oesophagus to cancer, and this may be evident in the gene expression profile and microRNA expression pattern in
Barrett’s oesophagus mucosa. We hypothesised that two miRNAs with inflammatory and oncogenic roles, miR-101
and miR-196a, are differentially expressed in Barrett’s oesophagus epithelium in patients with reflux treated
medically vs. surgically.
Findings: Mucosal tissue was obtained at endoscopy from patients with Barrett’s oesophagus whose reflux was
controlled by proton pump inhibitor (PPI) therapy (n = 20) or by fundoplication (n = 19). RNA was extracted and
the expression of miR-101 and miR-196a was measured using real-time reverse transcription - polymerase chain
reaction. There were no significant differences in miR-101 and miR-196a expression in Barrett’s oesophagus
epithelium in patients treated by PPI vs. fundoplication (p = 0.768 and 0.211 respectively). Secondary analysis
showed a correlation between miR-196a expression and Barrett’s oesophagus segment length (p = 0.014).
Conclusion: The method of reflux treatment did not influence the expression of miR-101 and miR-196a in Barrett’s
oesophagus. This data does not provide support to the hypothesis that surgical treatment of reflux better prevents
cancer development in Barrett’s oesophagus. The association between miR-196a expression and Barrett’s
oesophagus length is consistent with a tumour promoting role for miR-196a in Barrett’s oesophagus.
Background
Barrett’s oesophagus is characterised by the develop-
ment of a metaplastic columnar mucosa within the
distal oesophagus. This develops as a response to
gastro-oesophageal reflux. Its clinical significance is its
potential to become dysplastic, and then to progress in
some individuals to oesophageal adenocarcinoma.
Currently, Barrett’s oesophagus is the only identifiable
precursor lesion for oesophageal adenocarcinoma [1].
Treatment of gastro-oesophageal reflux in patients with
Barrett’s oesophagus is thought to be important, as onco-
genic progression may be associated with inflammation,
and inflammation can be minimised by effective control
of reflux [2]. Reflux control is achieved either by medica-
tion (usually proton-pump inhibitors - PPI’s) or surgery
(fundoplication). Although both effectively relieve reflux
symptoms, only surgery constructs a physical barrier
which prevents gastric contents actually entering the
oesophagus. By contrast, medication reduces gastric acid
production, and thereby changes the composition of the
refluxate. This means that some reflux continues to
occur, even though symptoms can be well controlled.
Also, because the duration of effect of medication can be
less than 24 hours [3], medical treatment can be asso-
ciated with breakthrough acid and/or bile reflux, and this
can have anti-apoptotic, proliferative and genotoxic
effects in Barrett’s oesophagus epithelium [4,5]. Hence, it
is can be hypothesised that the distal oesophageal epithe-
lium in patients with PPI treated Barrett’s oesophagus
may be more prone to ongoing inflammatory oncogenic
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stimuli, and this may be evident in the gene expression
profile exhibited in the Barrett’s oesophagus epithelium.
Supporting this, it has recently been reported that levels
of pro-inflammatory cytokines, including IL-1b, IL-1a,
and IL-8, are elevated in Barrett’s oesophagus epithelium
in patients treated with PPI’s, compared with patients
treated by fundoplication [6].
MicroRNAs (miRNAs) are 21-22 nucleotide long, non-
coding RNA segments, that regulate gene expression by
binding to complementary sequences in the 3’UTR of
target mRNAs, thereby interfering with mRNA transla-
tion [7]. Bioinformatic predictions estimate that a single
miRNA can regulate the expression of hundreds of
genes [8]. It is possible that miRNAs associated with
oncogenic and inflammatory processes may be differen-
tially expressed in Barrett’s oesophagus epithelium from
individuals who have medically versus surgically treated
gastro-oesophageal reflux disease. To explore this possi-
bility, we evaluated two miRNAs which are known to be
associated with oncogenic processes, miR-196a and
miR-101 [9-12], and we compared their expression in
Barrett’s oesophagus epithelium in patients with medi-
cally versus surgically treated reflux.
Methods and materials
Patient selection
Tissue samples for this study were obtained at endoscopy
from individuals who had previously been recruited into
two randomised trials of Barrett’s oesophagus ablation
techniques, conducted within our institution [13,14].
Entry criteria for the trials entailed: age 18-75 years,
endoscopy appearances consistent with Barrett’s oeso-
phagus, histopathology confirmation of metaplastic
columnar mucosa with features of intestinal metaplasia,
reflux symptoms fully controlled by either regular high
dose PPI medication, or surgery (fundoplication). Exclu-
sion criteria were: no evidence of Barrett’s oesophagus,
ulcerative oesophagitis at endoscopy, uncontrolled reflux
symptoms, high-grade dysplasia in Barrett’s oesophagus,
and oesophageal cancer. Full details of the recruitment of
individuals has been reported elsewhere [13,14]. For the
current study, endoscopy derived oesophageal mucosal
tissue biopsies were obtained from individuals with Bar-
rett’s oesophagus at the time of entry into the clinical
trials, before any ablative therapy had been undertaken.
Tissue samples were obtained from 20 individuals who
had gastro-oesophageal reflux controlled by PPI, and
from 19 individuals who had undergone a previous surgi-
cal fundoplication for the control of reflux. Of the
patients who had undergone surgery for reflux 10 had
undergone a Nissen (360°) fundoplication, 1 a posterior
partial fundoplication, and 8 an anterior partial fundopli-
cation. In all patients, reflux symptoms were fully con-
trolled at entry into the study according to the following
criteria: (1) no reflux symptoms, and an intact fundopli-
cation at endoscopy or (2) no reflux symptoms, consum-
ing regular PPI medication and no oesophagitis at
endoscopy. All individuals gave written informed consent
for participation in this study. The study protocol was
approved by the Flinders Clinical Research Ethics
Committee.
Tissue collection
Endoscopic biopsy samples were obtained according to a
modified Seattle Protocol; using endoscopic jumbo for-
ceps, commencing 1 cm above the gastro-oesophageal
junction, and then continuing every 2 cm proximally
along the length of the Barrett’s oesophagus. At each
level, 4 quadrant biopsies were obtained for conven-
tional histopathology analysis. An additional 2-3 endo-
scopic mucosal biopsies were obtained for molecular
biology studies (this study), and they were immediately
stored in RNAlater (Ambion) and frozen at -20°C until
required. For this study we used the RNAlater collected
biopsy samples collected from the most distal level of
endoscopically visualised Barrett’s oesophagus epithe-
lium, which was confirmed by histopathology to be
from columnar mucosa with intestinal metaplasia. These
samples were collected approximately 1 cm above the
gastroesophageal junction.
Biopsy processing, nucleic acid extraction, and
quantitative reverse transcription-polymerase chain
reaction (qRT-PCR) analysis
Selected endoscopic biopsies were thawed in RNAlater as
required. 30% of each sample was then dissected from
the thawed tissue sample, fixed in formalin, embedded in
paraffin, and then processed for conventional histo-
pathology. This step was used to confirm that the biopsy
contained only columnar epithelium with intestinal
metaplasia. The methods for this have described else-
where [15]. The remaining 70% of the thawed biopsy had
any remaining RNAlater removed, and was then pro-
cessed in Trizol (Invitrogen). Details of the RNA extrac-
tion procedure and qRT-PCR method have been
described fully in a previous report [16]. The following
Applied Biosystems assays were used for TaqMan® PCR:
miR-101, no. 002253; miR-196a, no. 000495; RNU44,
no.001094. MiR-101 and miR-196a expression was then
determined, and was normalised with small nuclear
RNA, RNU44 expression. Quantitative analysis was per-
formed using Q-Gene software [17].
Statistical Analysis
miRNA levels were extracted from the RotorGene soft-
ware and transferred into Microsoft Excel. The Mann-
Whitney U test was used to assess differences between
expression levels. Spearman’s correlation coefficient was
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used to evaluate correlations between miRNA expres-
sion and the length of the Barrett’s oesophagus segment.
P < 0.05 was determined to be statistically significant.
Results
Demographic and Barrett’s oesophagus associated para-
meters are summarised in Table 1. There were no sig-
nificant differences in the gender ratio and Barrett’s
oesophagus segment length between the groups of
patients whose reflux was treated medically vs. surgi-
cally. However, there was a significant difference in the
age of patients for the 2 study groups (p = 0.0039).
Table 2 summarises the expression of miR-101 and
miR-196a for the two treatment groups. The treatment
of gastro-oesophageal reflux (medical vs surgical) did
not reveal differential expression of either miRNA.
Further data analysis showed an association between
miR-196a expression levels and the length of the Bar-
rett’s oesophagus segment, but no association between
miR-101 and length. Table 3 summarises expression in
patients with Barrett’s oesophagus segment lengths of
less than or equal to 3 cm versus greater than 3 cm.
MiR-196a levels were significantly higher in individuals
with a Barrett’ segment length of more than 3 cm. We
also identified a significant correlation between the
length of the Barrett’s oesophagus segment and the
expression of miR-196a (rho = 0.389, p = 0.014, Spear-
man’s correlation coefficient), but not miR-101 (rho =
-0.183, p = 0.308).
Discussion
Barrett’s oesophagus is the only known risk factor for
the development of oesophageal adenocarcinoma, a can-
cer which has been rapidly increasing in incidence, par-
ticularly in male Caucasian populations [1]. It develops
following long standing gastro-oesophageal reflux, prob-
ably as a consequence of the reflux of both gastric acid
and duodenal content, the latter including bile acids and
other substances which are toxic to the normal oesopha-
geal mucosa [5].
Currently, medical treatment with PPIs is the first line
treatment for gastro-oesophageal reflux in patients with
Barrett’s oesophagus. PPIs block gastric acid production,
and thereby reduce the exposure of the oesophagus to
low pH. This reduces or eliminates symptoms of gastro-
oesophageal reflux. Unfortunately, PPIs can have a dura-
tion of effect of less than 24 hours, and this can mean
that PPIs are not fully effective in patients with severe
reflux [3]. As a consequence, higher dose or twice daily
PPI therapy is often required in patients with Barrett’s
oesophagus. However, even this does not eliminate
reflux in all patients, and some continue to reflux gastric
and duodenal content into the oesophagus. Ongoing
reflux of duodenal fluids which are rich in bile salts can
induce an inflammatory process in the oesophageal
mucosa, and bile salts substance are more toxic to cells
at a neutral pH [18]. The alternative treatment for reflux
is surgical. Wrapping the fundus of the stomach around
the distal oesophagus (fundoplication) creates a new
valve which physically prevents reflux. Fundoplication
for reflux has been shown to achieve excellent control
of reflux symptoms in approximately 90% of individuals
at 10 years follow-up [19]. Because a fundoplication cre-
ates a new valve, preventing both acid and bile exposure
in the oesophagus surgery reduces exposure of the oeso-
phageal mucosa to bile acids, and this might prevent
cancer development in Barrett’s oesophagus. Circum-
stantial evidence supporting this includes studies which
show that adenocarcinoma only occurs in the first 1 to
2 years follow up following fundoplication, but not at
late follow up [20]. It is suggested that only small unde-
tectable cancerous lesions, present before surgery, actu-
ally progress to cancer after fundoplication. Other
studies, however, have shown late cancer development
after fundoplication [21,22]. Irrespective of whether one
believes that antireflux surgery prevents cancer or not,
there is a consensus that reflux control should be maxi-
mised in patients with Barrett’s oesophagus, and that
this is important for cancer prevention.
In our study we selected 2 miRNAs for study in the
context of medically vs surgical treated gastro-oesopha-
geal reflux. MiRNA expression has been shown to be
associated with the development of many cancers, and
the expression of appropriately selected miRNAs might
inform the debate about medical vs surgical treatment
of reflux in patients with Barrett’s oesophagus, and the
potential for reflux control to impact on the progression
of Barrett’s oesophagus mucosa to cancer.
Table 1 Age, sex and Barrett’s esophagus segment length in patients with medically vs. surgically treated gastro-
esophageal reflux
Surgical (n = 19) Medical (n = 20) p value
Age (yrs) 50.0 (44.4, 54.6) 59.5 (55.4, 61.8) 0.0039
Gender (M:F) 16:3 15:5 0.6948
Barrett’s esophagus segment length (cm) 3.0 (2.5, 5.4) 3.0 (2.4, 4.1) 0.71
All figures are median with 95% confidence intervals. P values are derived from Mann-Whitney U test (Age and Barrett’s esophagus segment length), or Fisher’s
exact test (Gender).
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It is well understood that COX-2 is an inflammation-
associated protein. It is positively regulated by IL-1b in
Barrett’s oesophagus [23], and its expression increases
along the metaplasia - dysplasia - adenocarcinoma path-
way [24]. COX-2 levels are induced by gastro-oesophageal
reflux, and this is associated with increased proliferation
and resistance to apoptosis in Barrett’s oesophagus
mucosa [4]. Importantly, miR-101 directly targets COX-2,
and decreased miR-101 expression has been linked to
apoptosis resistance and increased cell growth in the
development of some cancers [11,12]. Whilst miR-101 has
not been studied in the context of inflammation or onco-
genic predisposition in Barrett’s oesophagus before, we
chose to study it in this context because IL-1b levels are
elevated in Barrett’s oesophagus mucosa from patients
with medically vs surgically treated reflux [6], IL-1b posi-
tively regulates COX-2 [23], and COX-2 is negatively
regulated by miR-101 [11,12]. Hence, we hypothesised
that a difference in miR-101 levels might be observed in
Barrett’s oesophagus mucosa from patients with medical
and surgically treated gastro-oesophageal reflux.
We selected miR-196a because a recent study by Maru
et al. provided evidence that increased levels of miR-
196a are associated with the progression of Barrett’s
oesophagus to adenocarcinoma [10]. Maru et al.
observed a step-wise progression in miR-196a expres-
sion along the metaplasia - dysplasia - adenocarcinoma
pathway. In another study they demonstrated that miR-
196a has growth promoting and anti-apoptotic proper-
ties in oesophageal adenocarcinoma cell lines, and that
it directly targets anti-inflammatory Annexin 1 [9].
Because of its demonstrated oncogenic and pro-inflam-
matory properties, we considered miR-196a to be a sui-
table candidate for our study.
In our study we observed no differences in miR-101 or
miR-196a expression in Barrett’s oesophagus epithelium
between patients with medically versus surgically treated
gastro-oesophageal reflux. Hence, our study failed to
support the proposal that surgical control of reflux
alters miRNA expression to reduce the risk of Barrett’s
oesophagus progressing to oesophageal adenocarcinoma.
However, the results of our study should also not be
interpreted as showing that the method of reflux control
in Barrett’s oesophagus does not influence cancer pro-
gression! An expanded range of biomarkers might
demonstrate different results. It is also possible that
miR-196a and miR-101 expression may not be sensitive
indicators of inflammatory and precancerous processes
in Barrett’s oesophagus epithelium, even though bioin-
formatic predictions support a role for these miRNAs in
targeting IL-1b, IL-1a, and IL-8 [25] (see miRecords at
http://mirecords.biolead.org/prediction_query.php).
Further, even if miR-196a and miR-101 do regulate
IL-1b, IL-1a, and IL-8 in Barrett’s epithelium, it is still
possible that these pro-inflammatory cytokines are pre-
sent at different levels in the two treatment groups in
the absence of differential miR-101 or miR-196a expres-
sion. This is because their regulation may be indepen-
dent of miRNAs in these therapeutic scenarios, or
dependent on other miRNAs which we did not assess.
As described above, IL-1b positively regulates COX-2, a
direct target of miR-101. In our study we did not assess
the expression of IL-1b or COX-2, although it would be
interesting to determine in future studies whether the
expression of one or both of these markers are inversely
correlated with miR-101 expression in Barrett’s oesopha-
gus epithelium.
Because the length of the Barrett’s oesophagus segment
has been shown to correlate with the severity of gastro-
oesophageal reflux [26-28], as well as the risk of progres-
sion to oesophageal adenocarcinoma [29], we tested a
secondary hypothesis that there might be an association
between miR-101 and/or miR-196a expression and the
length of the Barrett’s oesophagus segment. We found a
positive correlation between miR-196a expression and
the length of Barrett’s oesophagus. Although Barrett’s
oesophagus length has been correlated with DNA methy-
lation in gene promoters [30], to our knowledge only one
study has assessed associations between gene expression
and Barrett’s oesophagus length, and no associations
were observed [31]. Indirectly, our observation is in
agreement with the results of Maru et al. which support
the oncogenic potential of miR-196a in Barrett’s oeso-
phagus, and observations of an association between
Barrett’s oesophagus segment length and increased
cancer risk [29]. If the length of Barrett’s oesophagus
correlates with the risk of cancer development, our
results raise the possibility that miR-196a expression
might be used as a biomarker for stratification of cancer
risk in patients with Barrett’s oesophagus. This possibility
Table 3 Association between miR-196a and miR-101
expression vs. Barrett’s esophagus segment length
Barrett’s ≤ 3 cm Barrett’s > 3 cm p value
miR-101 0.0099 (0.0073, 0.0130) 0.0082 (0.0069, 0.0144) p = 0.920
miR-196a 0.0010 (0.0009, 0.0028) 0.0033 (0.0022, 0.0064) p = 0.014
All figures are median of normalised relative expression (95% confidence
intervals). The p value is derived from a Mann-Whitney U test.
Table 2 Relative expression levels for miRNAs in patients
with Barrett’s oesophagus with medically vs. surgically
treated gastro-esophageal reflux
Surgical (n = 19) Medical (n = 20) p value
miR-101 0.0080 (0.0071, 0.0145) 0.0102 (0.0073, 0.0126) p = 0.768
miR-196a 0.0017 (0.0011, 0.0032) 0.0022 (0.0018, 0.0054) p = 0.211
All figures are median of normalised relative expression (95% confidence
intervals).
The p value is derived from a Mann-Whitney U test.
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will need to be evaluated in further studies. Such studies
might entail comparing the expression of miR-196a in
Barrett’s oesophagus from patients who have progressed
to cancer vs. those that have not. This would require
either longitudinal collection of tissues from a Barrett’s
oesophagus surveillance cohort, or retrospective collec-
tion of old paraffin embedded surveillance biopsy mate-
rial from individuals who have progressed from Barrett’s
oesophagus to cancer vs those without cancer. The sensi-
tivity and specificity for miR-196a expression levels vs
cancer progression could be determined in this way.
There are some limitations to our study, and the data
should be interpreted carefully. Firstly, there was a sig-
nificant difference in age between the two reflux treat-
ment groups, and we cannot eliminate the possibility
that this might have influenced outcomes study out-
comes. We hypothesise that this difference was due to a
selection bias towards different treatments based on age.
Secondly, we did not include any reference control tis-
sues, so we cannot exclude the possibility that medical
and surgical therapy affect miR-196a and miR-101
expression to a similar extent. Squamous epithelium
from more proximally in the oesophagus could easily be
obtained, but it is not and appropriate control for this
study, as miRNA expression is tissue specific [10] and
our study was focussed on Barrett’s oesophagus mucosa.
The most appropriate control tissue would be Barrett’s
oesophagus mucosa from patients with uncontrolled
reflux, i.e. patients who had not undergone antireflux
surgery who were also not using antireflux medication.
Finally, we only assessed 2 miRNA biomarkers, and a
different methodology would be required to more com-
prehensively test our original hypothesis. This could be
undertaken initially as a microarray based discovery
study, followed by PCR based validation of relevant
miRNA markers shown to differ in Barrett’s oesophagus
mucosa from patients with medically vs. surgically trea-
ted reflux. Further, 24 hour ambulatory pH data might
better inform the quality of reflux control and its poten-
tial impact on miRNA expression. Nevertheless, all of
the patients in our study had clinically effective reflux
control, and endoscopy findings which supported the
clinical assessment, suggesting that the study groups
were representative of patients whose reflux was mana-
ged by either effective PPI therapy or an effective
fundoplication.
In summary, we found no evidence for differential
expression of the oncogenic and inflammatory related
miRNAs - miR-101 and miR-196a, in Barrett’s oesopha-
gus epithelium from medically versus surgically treated
patients. Further studies, including microarray based
analyses, are warranted to determine if any microRNAs
are differentially expressed in Barrett’s oesophagus
mucosa in patients with gastro-oesophageal reflux
treated with either PPI’s or surgical fundoplication. We
found a novel positive association between the expres-
sion of miR-196a and the length of the Barrett’s oeso-
phagus segment, consistent with a hypothesised tumour
promoting role for miR-196a in Barrett’s oesophagus.
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